Long-term biological monitoring of environmental quality around a solid waste landfill assessed with lichens.

L. Paoli,A. Corsini,V. Bigagli,J Vannini,C. Bruscoli,S. Loppi

DOI: https://doi.org/10.1016/j.envpol.2011.09.028

IF: 8.9

2012-02-01

Environmental Pollution

Abstract:

What problem does this paper attempt to address?

A Comprehensive Overview On The Most Recent Trends In Covid-19 Diagnosis, Treatment Options And Vaccine Development Status

Jayendrakumar Patel,Shalin Parikh,Shwetaben Patel

DOI: https://doi.org/10.53049/tjopam.2021.v001i01.001

2021-06-13

The Journal of Pharmaceutical Sciences and Medicinal Research

Abstract:The global pandemic produced by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first appeared in Wuhan, China, in December 2019 and which then spread rapidly, made it difficult to find or develop effective medications for its prevention and treatment. Therefore, the first stage is necessitating the use of a precise and quick diagnostic method to detect SARS-CoV-2 infected patient followed by effective patient isolation and the commencement of early treatment, which can range from supportive therapy to specialised medications such corticosteroids, antiviral medications, antibiotics, and the recently introduced convalescent plasma. Despite the extraordinary developments in advanced medicinal system, no confirmed viable medicines exist at this time. Rapid research on SARS CoV-2 epidemiology has led to the discovery of certain new targets for prospective therapeutic treatments. Many therapeutic options have been evaluated, and clinical studies are proceeding at a breakneck speed. However, there is a lot of room for more study into finding cost-effective and safer medicines, vaccinations, and measures to ensuring that COVID-19 preventive and treatment programmes are available to everyone. The goal of this study is to compile all of the current advancements in the worldwide medical system in the fight against COVID-19.

English Else
COVID-19: vaccination, therapeutics and a review of the science and public health

Sanjit Kumar Shah,Kritick Bhandari,Avish Shah,Gopal Chaurasiya

DOI: https://doi.org/10.1097/MS9.0000000000002374

2024-07-17

Abstract:COVID-19, stemming from the SARS-CoV-2 virus, has initiated a worldwide respiratory pandemic. Remarkable headway has been made in the realm of vaccination, as nearly every nation has initiated COVID-19 vaccine deployment. However, a mere 32.6% of individuals in low-income countries have received only a single vaccine dose. Unprecedented research and development endeavors have yielded over 170 COVID-19 vaccines, several of which are now in practical use. These vaccines have demonstrated remarkable efficacy in averting severe illness, hospitalization, and fatalities from COVID-19, even against emerging variants. Research pursuits persist, concentrating on novel vaccine technologies, oral and nasal vaccines, broader coronavirus protection, and vaccine combinations. In the realm of therapeutics, there have been significant strides in developing oral antiviral medications and monoclonal antibodies. Nonetheless, challenges in COVID-19 vaccination persist, encompassing issues of hesitancy, accessibility, financial barriers, knowledge gaps, and logistical hindrances. Robust monitoring via global agencies and reporting systems remains pivotal. Strategies for enhancing vaccination efficacy are rooted in fostering trust, countering misinformation, and expanding access. As for therapeutics, the approach involves dedicated research, clinical trials, regulatory streamlining, stockpiling, and international collaboration. Telemedicine and public awareness campaigns play integral roles in this effort, with coordination being the linchpin for preserving lives and mitigating the disease's impact. The global campaign against COVID-19 has witnessed substantial advancements, with an ongoing research focus on developing vaccines and therapeutics that are not only more accessible and affordable but also more effective, particularly for populations in low-income countries and vulnerable communities.
COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development

Narjess Bostanghadiri,Pardis Ziaeefar,Morvarid Golrokh Mofrad,Parsa Yousefzadeh,Ali Hashemi,Davood Darban-Sarokhalil

DOI: https://doi.org/10.1155/2023/1879554

2023-08-30

BioMed Research International

Abstract:The world is presently in crisis facing an outbreak of a health-threatening microorganism known as COVID-19, responsible for causing uncommon viral pneumonia in humans. The virus was first reported in Wuhan, China, in early December 2019, and it quickly became a global concern due to the pandemic. Challenges in this regard have been compounded by the emergence of several variants such as B.1.1.7, B.1.351, P1, and B.1.617, which show an increase in transmission power and resistance to therapies and vaccines. Ongoing researches are focused on developing and manufacturing standard treatment strategies and effective vaccines to control the pandemic. Despite developing several vaccines such as Pfizer/BioNTech and Moderna approved by the U.S. Food and Drug Administration (FDA) and other vaccines in phase 4 clinical trials, preventive measures are mandatory to control the COVID-19 pandemic. In this review, based on the latest findings, we will discuss different types of drugs as therapeutic options and confirmed or developing vaccine candidates against SARS-CoV-2. We also discuss in detail the challenges posed by the variants and their effect on therapeutic and preventive interventions.

biotechnology & applied microbiology,medicine, research & experimental
Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development

Jubeda Begum,Nasir Akbar Mir,Kapil Dev,Bidyarani Buyamayum,Mohd Yaqoob Wani,Meesam Raza

DOI: https://doi.org/10.1111/tbed.13804

Abstract:The outbreak of coronavirus disease 2019 (COVID-19) as a pandemic has shaken the global health system and economy by their roots. This epidemic is still spreading and showing no signs of decreasing trend. Vaccination could be the only effective and economical means to control this pandemic. A number of research institutions and pharmaceutical companies have plunged into the race of vaccine development against COVID-19 which are in various stages of development. An intriguing fact of coronavirus infections is that in every decade of the 21st century there is a new major coronavirus epidemic, namely, severe acute respiratory syndrome (SARS) in 2002, Middle East respiratory syndrome (MERS) in 2012, and now COVID-19; and such epidemics are expected in future too. Since most of the biological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still obscure, the scientists are relying on the information available on SARS-CoV and to some extent on MERS-CoV for designing and developing COVID-19 vaccines. But there is a need of vigorous testing for immunogenicity, safety, efficacy, and level of protection conferred in the hosts. This review focuses on the challenges and prospects of vaccine development against COVID-19. It highlights seriousness, bottlenecks in vaccine development, possible vaccine candidates, different vaccine strategies, safety evaluation issues, and vaccine production processes pertaining to COVID-19 based on the knowledge acquired on SARS and MERS vaccine development in the past.
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu M. Bennet,Jayanthi Wolf,Rodrigo Laureano,Rani S. Sellers

DOI: https://doi.org/10.1177/0192623320959090

2020-09-14

Toxicologic Pathology

Abstract:The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an urgent need to develop safe and efficacious vaccines. The scientific community has made tremendous efforts to understand the disease, and unparalleled efforts are ongoing to develop vaccines and treatments. Toxicologists and pathologists are involved in these efforts to test the efficacy and safety of vaccine candidates. Presently, there are several SARS-CoV-2 vaccines in clinical trials, and the pace of vaccine development has been highly accelerated to meet the urgent need. By 2021, efficacy and safety data from clinical trials are expected, and potentially a vaccine will be available for those most at risk. This review focuses on the ongoing SARS-CoV-2 vaccine development efforts with emphasis on the nonclinical safety assessment and discusses emerging preliminary data from nonclinical and clinical studies. It also provides a brief overview on vaccines for other coronaviruses, since experience gained from these can be useful in the development of SARS-CoV-2 vaccines. This review will also explain why, despite this unprecedented pace of vaccine development, rigorous standards are in place to ensure nonclinical and clinical safety and efficacy. [Box: see text]

pathology,toxicology
Recent developments and opportunities in fighting COVID-19

Vikram Rao,Subrat Kumar Bhattamisra

DOI: https://doi.org/10.2174/2666796701999201204120422

2021-07-01

Coronaviruses

Abstract:Background: COVID-19, a Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCov- 2), was first diagnosed in the patients from Wuhan, China, in December 2019. Within a couple of months of infection, it was declared as pandemic by the World health organization. COVID-19 has become the most contagious infection with a serious threat to global health. In this review, we aimed to discuss the pathogenesis, diagnostics, current treatments and potential vaccines for COVID-19. Methods: An extensive literature search was conducted using keywords “COVID-19”; “Coronavirus”; “SARS-Cov-2”; “SARS” in public domains of Google, Google scholar, PubMed, and ScienceDirect. Selected articles were used to construct this review. Results: SARS-Cov-2 uses the Spike (S) protein on its surface to recognize the receptor on angiotensin- converting enzyme 2 (ACE2) and bind with 10-folds greater affinity than SARS-Cov-1. Molecular assays and immunoassays are the most frequently used tests, whereas computed tomography (CT) scans and artificial intelligence enabled diagnostic tools were also used in patients. In therapeutic treatment, few drugs were repurposed and about 23 therapeutic molecules, including the repurposed drugs are at different stages of the clinical trial. Similarly, the development of vaccines is also in the pipeline. Few countries have managed well to contain the spread by rapid testing and identifying the clusters. Conclusion: Till now, the acute complications and mortality of COVID-19 have been linked to pre-existing comorbid conditions or age. Besides the development of therapeutic strategies that include drugs and vaccine, the long term implication of COVID-19 infection in terms of the disorder/ disability in the cured/discharged patients is a new area to investigate.
COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2

Rohitas Deshmukh,Ranjit K Harwansh,Akash Garg,Sakshi Mishra,Rutvi Agrawal,Rajendra Jangde

DOI: https://doi.org/10.2174/0113892029291098240129113500

2024-03-13

Current Genomics

Abstract:SARS-CoV-2 is a highly contagious and transmissible viral infection that first emerged in 2019 and since then has sparked an epidemic of severe respiratory problems identified as "coronavirus disease 2019" (COVID-19) that causes a hazard to human life and safety. The virus developed mainly from bats. The current epidemic has presented a significant warning to life across the world by showing mutation. There are different tests available for testing Coronavirus, and RTPCR is the best, giving more accurate results, but it is also time-consuming. There are different options available for treating n-CoV-19, which include medications such as Remdesivir, corticosteroids, plasma therapy, Dexamethasone therapy, etc. The development of vaccines such as BNT126b2, ChAdOX1, mRNA-1273 and BBIBP-CorV has provided great relief in dealing with the virus as they decreased the mortality rate. BNT126b2 and ChAdOX1 are two n-CoV vaccines found to be most effective in controlling the spread of infection. In the future, nanotechnology-based vaccines and immune engineering techniques can be helpful for further research on Coronavirus and treatment of this deadly virus. The existing knowledge about the existence of SARS-- CoV-2, along with its variants, is summarized in this review. This review, based on recently published findings, presents the core genetics of COVID-19, including heritable characteristics, pathogenesis, immunological biomarkers, treatment options and clinical updates on the virus, along with patents.

genetics & heredity,biochemistry & molecular biology
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Ali A. Rabaan,Shamsah H. Al-Ahmed,Ranjit Sah,Ruchi Tiwari,Mohd. Iqbal Yatoo,Shailesh Kumar Patel,Mamta Pathak,Yashpal Singh Malik,Kuldeep Dhama,Karam Pal Singh,D. Katterine Bonilla-Aldana,Shafiul Haque,Dayron F. Martinez-Pulgarin,Alfonso J. Rodriguez-Morales,Hakan Leblebicioglu

DOI: https://doi.org/10.1186/s12941-020-00384-w

2020-09-02

Annals of Clinical Microbiology and Antimicrobials

Abstract:Abstract A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 210 countries while affecting more than 25 million people and causing more than 843,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus , like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs, and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. To date, August 30, 2020, no effective, proven therapeutic antibodies or specific drugs, and vaccines have turned up. In this review article, we describe the underlying molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.

microbiology
The COVID-19 Vaccines: Recent Development, Challenges and Prospects

Yuxin Yan,Yoongxin Pang,Zhuoyi Lyu,Ruiqi Wang,Xinyun Wu,Chong You,Haitao Zhao,Sivakumar Manickam,Edward Lester,Tao Wu,Cheng Heng Pang

DOI: https://doi.org/10.3390/vaccines9040349

2021-04-05

Vaccines

Abstract:The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the “new normal” and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public.

immunology,medicine, research & experimental
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Monika Kumari,Ruei-Min Lu,Mu-Chun Li,Jhih-Liang Huang,Fu-Fei Hsu,Shih-Han Ko,Feng-Yi Ke,Shih-Chieh Su,Kang-Hao Liang,Joyce Pei-Yi Yuan,Hsiao-Ling Chiang,Cheng-Pu Sun,I.-Jung Lee,Wen-Shan Li,Hsing-Pang Hsieh,Mi-Hua Tao,Han-Chung Wu

DOI: https://doi.org/10.1186/s12929-022-00852-9

2022-09-13

Journal of Biomedical Science

Abstract:The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. To help address some of the main problems, the scientific community has designed vaccines, diagnostic tools and therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The rapid pace of technology development, especially with regard to vaccines, represents a stunning and historic scientific achievement. Nevertheless, many challenges remain to be overcome, such as improving vaccine and drug treatment efficacies for emergent mutant strains of SARS-CoV-2. Outbreaks of more infectious variants continue to diminish the utility of available vaccines and drugs. Thus, the effectiveness of vaccines and drugs against the most current variants is a primary consideration in the continual analyses of clinical data that supports updated regulatory decisions. The first two vaccines granted Emergency Use Authorizations (EUAs), BNT162b2 and mRNA-1273, still show more than 60% protection efficacy against the most widespread current SARS-CoV-2 variant, Omicron. This variant carries more than 30 mutations in the spike protein, which has largely abrogated the neutralizing effects of therapeutic antibodies. Fortunately, some neutralizing antibodies and antiviral COVID-19 drugs treatments have shown continued clinical benefits. In this review, we provide a framework for understanding the ongoing development efforts for different types of vaccines and therapeutics, including small molecule and antibody drugs. The ripple effects of newly emergent variants, including updates to vaccines and drug repurposing efforts, are summarized. In addition, we summarize the clinical trials supporting the development and distribution of vaccines, small molecule drugs, and therapeutic antibodies with broad-spectrum activity against SARS-CoV-2 strains.

cell biology,medicine, research & experimental
Diagnosis for COVID-19: current status and future prospects

Md Alamgir Kabir,Rajib Ahmed,Sheikh Muhammad Asher Iqbal,Rasheduzzaman Chowdhury,Ramasamy Paulmurugan,Utkan Demirci,Waseem Asghar

DOI: https://doi.org/10.1080/14737159.2021.1894930

Abstract:Introduction: Coronavirus disease 2019 (COVID-19), a respiratory illness caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had its first detection in December 2019 in Wuhan (China) and spread across the world. In March 2020, the World Health Organization (WHO) declared COVID-19 a pandemic disease. The utilization of prompt and accurate molecular diagnosis of SARS-CoV-2 virus, isolating the infected patients, and treating them are the keys to managing this unprecedented pandemic. International travel acted as a catalyst for the widespread transmission of the virus.Areas covered: This review discusses phenotype, structural, and molecular evolution of recognition elements and primers, its detection in the laboratory, and at point of care. Further, market analysis of commercial products and their performance are also evaluated, providing new ways to confront the ongoing global public health emergency.Expert commentary: The outbreak for COVID-19 created mammoth chaos in the healthcare sector, and still, day by day, new epicenters for the outbreak are being reported. Emphasis should be placed on developing more effective, rapid, and early diagnostic devices. The testing laboratories should invest more in clinically relevant multiplexed and scalable detection tools to fight against a pandemic like this where massive demand for testing exists.
Status Report on COVID-19 Vaccines Development

Arun Kumar,William E. Dowling,Raúl Gómez Román,Amol Chaudhari,Celine Gurry,Tung Thanh Le,Stig Tollefson,Carolyn E Clark,Valentina Bernasconi,Paul A Kristiansen

DOI: https://doi.org/10.1007/s11908-021-00752-3

2021-04-14

Current Infectious Disease Reports

Abstract:Abstract Purpose of Review The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected lives of billions of individuals, globally. There is an urgent need to develop interventions including vaccines to control the ongoing pandemic. Recent Findings Development of tools for fast-tracked testing including small and large animal models for vaccine efficacy analysis, assays for immunogenicity assessment, critical reagents, international biological standards, and data sharing allowed accelerated development of vaccines. More than 300 vaccines are under development and 9 of them are approved for emergency use in various countries, with impressive efficacy ranging from 50 to 95%. Recently, several new SARS-CoV-2 variants have emerged and are circulating globally, and preliminary findings imply that some of them may escape immune responses against previous variants and diminish efficacy of current vaccines. Most of these variants acquired new mutations in their surface protein (Spike) which is the antigen in most of the approved/under development vaccines. Summary In this review, we summarize novel and traditional approaches for COVID-19 vaccine development including inactivated, attenuated, nucleic acid, vector and protein based. Critical assessment of humoral and cell-mediated immune responses induced by vaccines has shown comparative immunogenicity profiles of various vaccines in clinical phases. Recent reports confirmed that some currently available vaccines provide partial to complete protection against emerging SARS-CoV-2 variants. If more mutated variants emerge, current vaccines might need to be updated accordingly either by developing vaccines matching the circulating strain or designing multivalent vaccines to extend the breadth.

infectious diseases
An Appraisal of the Current Scenario in Vaccine Research for COVID-19

Wai Chin Chong,Dinesh K. Chellappan,Shakti D. Shukla,Gregory M. Peterson,Rahul P. Patel,Niraj Kumar Jha,Rajaraman D. Eri,Kamal Dua,Murtaza M. Tambuwala,Madhur D. Shastri

DOI: https://doi.org/10.3390/v13071397

2021-07-18

Viruses

Abstract:The recent coronavirus disease 2019 (COVID-19) outbreak has drawn global attention, affecting millions, disrupting economies and healthcare modalities. With its high infection rate, COVID-19 has caused a colossal health crisis worldwide. While information on the comprehensive nature of this infectious agent, SARS-CoV-2, still remains obscure, ongoing genomic studies have been successful in identifying its genomic sequence and the presenting antigen. These may serve as promising, potential therapeutic targets in the effective management of COVID-19. In an attempt to establish herd immunity, massive efforts have been directed and driven toward developing vaccines against the SARS-CoV-2 pathogen. This review, in this direction, is aimed at providing the current scenario and future perspectives in the development of vaccines against SARS-CoV-2.

virology
Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic

Bidhan C. Dhar

DOI: https://doi.org/10.1007/s00216-022-03918-7

2022-02-25

Analytical and Bioanalytical Chemistry

Abstract:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused COVID-19 pandemic has transmitted to humans in practically all parts of the world, producing socio-economic turmoil. There is an urgent need for precise, fast, and affordable diagnostic testing to be widely available for detecting SARS-CoV-2 and its mutations in various phases of the disease. Early diagnosis with great precision has been achieved using real-time polymerase chain reaction (RT-PCR) and similar other molecular methods, but theseapproaches are costly and involve rigorous processes that are not easily obtainable. Conversely, immunoassays that detect a small number of antibodies have been employed for quick, low-cost tests, but their efficiency in diagnosing infected people has been restricted. The use of biosensors in the detection of SARS-CoV-2 is vital for the COVID-19 pandemic’s control. This review gives an overview of COVID-19 diagnostic approaches that are currently being developed as well as nanomaterial-based biosensor technologies, to aid future technological advancement and innovation. These approaches can be integrated into point-of-care (POC) devices to quickly identify a large number of infected patients and asymptomatic carriers. The ongoing research endeavors and developments in complementary technologies will play a significant role in curbing the spread of the COVID-19 pandemic and fill the knowledge gaps in current diagnostic accuracy and capacity.Graphical abstract

chemistry, analytical,biochemical research methods
COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines

Mohd Iqbal Yatoo,Zeenat Hamid,Oveas Rafiq Parray,Aasim Habib Wani,Abrar Ul Haq,Archana Saxena,Shailesh Kumar Patel,Mamta Pathak,Ruchi Tiwari,Yashpal Singh Malik,Ranjit Sah,Ali A Rabaan,Alfonso J Rodriguez Morales,Kuldeep Dhama

DOI: https://doi.org/10.1080/21645515.2020.1788310

2020-12-01

Abstract:The COVID-19 pandemic caused by SARS-CoV-2 has spread rapidly. To date, countries have relied on the prevention of the disease through isolation, quarantine, and clinical care of affected individuals. However, studies on the roles of asymptomatic and mildly infected subjects in disease transmission, use of antiviral drugs, and vaccination of the general population will be very important for mitigating the effects of the eventual return of this pandemic. Initial investigations are ongoing to evaluate antigenic structures of SARS-CoV-2 and the immunogenicity of vaccine candidates. There also is a need to comprehensively compile the details of previous studies on SARS-related vaccines that can be extrapolated to identify potent vaccine targets for developing COVID-19 vaccines. This review aims to analyze previous studies, current status, and future possibilities for producing SARS-CoV-2 vaccines.
[COMPARISONS OF AHG TRANSFUSIONS WITH TOTAL BLOOD TRANSFUSIONS IN 3 CASES OF HEMOPHILIA A].

N. Bagriaçik

1963-08-01

Abstract:
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

DOI: https://doi.org/10.1007/s40265-024-02013-8

2024-04-24

Drugs

Abstract:The COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly 7 million deaths, according to the World Health Organization (WHO). Leveraging rapid development, accelerated vaccine approval processes, and large-scale production of various COVID-19 vaccines using different technical platforms, the WHO declared an end to the global health emergency of COVID-19 on May 5, 2023. Current COVID-19 vaccines encompass inactivated, live attenuated, viral vector, protein subunit, nucleic acid (DNA and RNA), and virus-like particle (VLP) vaccines. However, the efficacy of these vaccines is diminishing due to the constant mutation of SARS-CoV-2 and the heightened immune evasion abilities of emerging variants. This review examines the impact of the COVID-19 pandemic, the biological characteristics of the virus, and its diverse variants. Moreover, the review underscores the effectiveness, advantages, and disadvantages of authorized COVID-19 vaccines. Additionally, it analyzes the challenges, strategies, and future prospects of developing a safe, broad-spectrum vaccine that confers sufficient and sustainable immune protection against new variants of SARS-CoV-2. These discussions not only offer insight for the development of next-generation COVID-19 vaccines but also summarize experiences for combating future emerging viruses.

pharmacology & pharmacy,toxicology
Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review

Keshav S. Moharir,Sumit K. Arora,Subhash R. Yende,Govind K. Lohiya,Sapan K. Shah

DOI: https://doi.org/10.2174/2666958702101010065

2021-08-11

The Open COVID Journal

Abstract:Coronavirus Infectious Disease (COVID-19) has taken heavy toll on human lives and world economy across the globe. Till date, there is no specific treatment and pathological effects in COVID-19 are continuously evolving. The governments and authorities have announced various measures for personal care with use of face masks, physical distancing and prohibition of mass gatherings. These measures have certainly helped to contain the disease but with substantial economic slowdown. Thus mass immunization by vaccination is the top priority. With knowledge of MERS-SARS (Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome) in hand, researchers are rushing to vaccine development against SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) with newer technological platforms. However, the challenge lies in proving safety, quality and efficacy of vaccine with its resilience to manufacture it in large scales within stipulated time frame. The time consuming nature of classical phased clinical trials are substituted by human volunteer challenge with vaccination of humans engaging undertrial vaccine. This review discusses about various technology platforms being used and tried, their types and challenges in development of vaccine for SARS-CoV-2. Briefly, Indian perspective is also discussed in the race of vaccine development.
Advancements in Testing Strategies for COVID-19

Rabia Asghar,Madiha Rasheed,Jalees ul Hassan,Mohsin Rafique,Mashooq Khan,Yulin Deng

DOI: https://doi.org/10.3390/bios12060410

2022-06-14

Biosensors

Abstract:The SARS-CoV-2 coronavirus, also known as the disease-causing agent for COVID-19, is a virulent pathogen that may infect people and certain animals. The global spread of COVID-19 and its emerging variation necessitates the development of rapid, reliable, simple, and low-cost diagnostic tools. Many methodologies and devices have been developed for the highly sensitive, selective, cost-effective, and rapid diagnosis of COVID-19. This review organizes the diagnosis platforms into four groups: imaging, molecular-based detection, serological testing, and biosensors. Each platform's principle, advancement, utilization, and challenges for monitoring SARS-CoV-2 are discussed in detail. In addition, an overview of the impact of variants on detection, commercially available kits, and readout signal analysis has been presented. This review will expand our understanding of developing advanced diagnostic approaches to evolve into susceptible, precise, and reproducible technologies to combat any future outbreak.
Development of SARS-CoV-2 Vaccine: Challenges and Prospects

Tooba Mahboob,Amni Adilah Ismail,Muhammad Raza Shah,Mohammed Rahmatullah,Maria de Lourdes Pereira,Christophe Wiart,Polrat Wilairatana,Mogana Rajagopal,Veeranoot Nissapatorn,Alok K. Paul,Karma G. Dolma

DOI: https://doi.org/10.3390/diseases11020064

2023-04-20

Diseases

Abstract:The WHO declared coronavirus disease 2019 (COVID-19) a pandemic in March 2020, which was caused by novel coronavirus severe acute respiratory coronavirus 2 (SARS-CoV-2). SARS-CoV-2 made its first entry into the world in November 2019, and the first case was detected in Wuhan, China. Mutations in the SARS-CoV-2 genome distressed life in almost every discipline by the extended production of novel viral variants. In this article, authorized SARS-CoV-2 vaccines including mRNA vaccines, DNA vaccines, subunit vaccines, inactivated virus vaccines, viral vector vaccine, live attenuated virus vaccines and mix and match vaccines will be discussed based on their mechanism, administration, storage, stability, safety and efficacy. The information was collected from various journals via electronic searches including PubMed, Science Direct, Google Scholar and the WHO platform. This review article includes a brief summary on the pathophysiology, epidemiology, mutant variants and management strategies related to COVID-19. Due to the continuous production and unsatisfactory understanding of novel variants of SARS-CoV-2, it is important to design an effective vaccine along with long-lasting protection against variant strains by eliminating the gaps through practical and theoretical knowledge. Consequently, it is mandatory to update the literature through previous and ongoing trials of vaccines tested among various ethnicities and age groups to gain a better insight into management strategies and combat complications associated with upcoming novel variants of SARS-CoV-2.

Long-term biological monitoring of environmental quality around a solid waste landfill assessed with lichens.

A Comprehensive Overview On The Most Recent Trends In Covid-19 Diagnosis, Treatment Options And Vaccine Development Status

COVID-19: vaccination, therapeutics and a review of the science and public health

COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development

Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Recent developments and opportunities in fighting COVID-19

COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

The COVID-19 Vaccines: Recent Development, Challenges and Prospects

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Diagnosis for COVID-19: current status and future prospects

Status Report on COVID-19 Vaccines Development

An Appraisal of the Current Scenario in Vaccine Research for COVID-19

Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic

COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines

[COMPARISONS OF AHG TRANSFUSIONS WITH TOTAL BLOOD TRANSFUSIONS IN 3 CASES OF HEMOPHILIA A].

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review

Advancements in Testing Strategies for COVID-19

Development of SARS-CoV-2 Vaccine: Challenges and Prospects